Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03748186 · ClinicalTrials.gov registry record · Phase 1
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
A Phase 1 study, sponsored by Sutro Biopharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 136
- Enrollment target
NCT03748186 is a Phase 1 study that has completed, run by Sutro Biopharma. The registered enrollment target is 136 participants.
The verdict
NCT03748186, a Phase 1 study, has completed, sponsored by Sutro Biopharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 136 participants
- Enrollment target
Study Summary
Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
Interventions
- DRUG STRO-002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2019-02-01 |
| Est. Completion | 2024-06-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03748186
The ClinicalTrials.gov registry entry for NCT03748186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sutro Biopharma, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which STRO-002 is the first listed.
NCT03748186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03748186 about?
NCT03748186 is a clinical study titled "Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers". Phase 1 trial to study the safety, pharmacokinetics and preliminary efficacy of STRO-002 given intravenously every 3 weeks.
What is the current status of trial NCT03748186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 136 participants. The study started on 2019-02-01. Estimated completion is 2024-06-04.
What interventions are being tested in trial NCT03748186?
The interventions under investigation include: STRO-002 (DRUG).
Who is sponsoring clinical trial NCT03748186?
This trial is sponsored by Sutro Biopharma, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.